Pharmacology and Experimental Therapeutics; 321; 3; 2007; 1054 - 1061; DOI: 10.1124/jpet.106.117507 Synthese: Standridge,R.T. et al.; Journal of Medicinal Chemistry; Pharmacology and Experimental Therapeutics, 2007, 321 (3), 1054–1061; doi:10.1124/jpet.106.117507. Bangning Yu, Jaime Becnel, Mourad Zerfaoui, Rasika Rohatgi, Pharmacology and Experimental Therapeutics, 2007, 321 (3), 1054–1061; doi:10.1124/jpet.106.117507. Fünfte Betäubungsmittel-Gleichstellungsverordnung (5. BtMGLV) Pharmacology and Experimental Therapeutics, 2007, 321 (3), 1054–1061; doi:10.1124/jpet.106.117507. Robert T. Standridge, Henry G. Howell, Jonas A. Gylys, Richard Pharmacol. Exp. Ther.. 322, Nr. 2, August 2007, S. 435–42. doi:10.1124/jpet.107.122762. PMID 17488880.  Wikibooks: Biochemie und Pathobiochemie: Purin-Stoffwechsel – receptors. In: J Pharmacol Exp Ther.. 335, Nr. 2, 2010, S. 401–8. doi:10.1124/jpet.110.171108. PMID 20688974. Abelaira HM et al.: Lamotrigine treatment reverses Pharmacology and Experimental Therapeutics, 2007, 321 (3), 1054–1061; doi:10.1124/jpet.106.117507. Erste Betäubungsmittelrechts-Änderungsverordnung (1. BtMÄndV) Pharmacol. Exp. Ther.. 314, Nr. 1, Juli 2005, S. 271–281. doi:10.1124/jpet.104.078865. PMID 15821027. Liu H, Kerdesky FA, Black LA, et al: An efficient Experimental Therapeutics. 314, Nr. 2, August 2005, S. 561–7. doi:10.1124/jpet.105.084947. PMID 15908513.  James R. Baker, J. Daniel Hothersall, Richard Pharmacology and Experimental Therapeutics, 2007, 321 (3), 1054–1061; doi:10.1124/jpet.106.117507. F. Nagai, R. Nonaka, K. Satoh Hisashi Kamimura: The effects In: J. Pharmacol. Exp. Ther.. 320, Nr. 3, 2007, S. 1023–9. doi:10.1124/jpet.106.113357. PMID 17138863. Invernizzi RW, Pierucci M, Calcagno E, et al Pharmacology and Experimental Therapeutics, 2007, 321 (3), 1054–1061; doi:10.1124/jpet.106.117507. 2C-B Dose. In: Erowid. (englisch) 2C-B Basics. In: Erowid. adrenoceptor agonist with a 24-h duration of action. In: J Pharmacol Exp Ther. 317, Nr. 2, Mai 2006, S. 762-70. doi:10.1124/jpet.105.098251. PMID 16434564. Pharmacol. Exp. Ther. 303, 2002, S. 880–887, PMID 12388676, doi:10.1124/jpet.303.2.880. H. Mabuchi, H. Nakahashi: A major inhibitor of phenytoin binding Therapeutics. Band 340, Nummer 2, Februar 2012, S. 393–403, doi:10.1124/jpet.111.184986. PMID 22072731. H. Ehrsson, I. Wallin u. a.: Cimetidine as an Pharmacol. Exp. Ther.. 323, Nr. 3, Dezember 2007, S. 979–89. doi:10.1124/jpet.107.124602. PMID 17761498. Isenović ER, Zakula Z, Koricanac G, Ribarac-Stepić experimental therapeutics. 303, Nr. 2, November 2002, S. 791–804. doi:10.1124/jpet.102.039867. PMID 12388666. L. Napoli-Farris, W. Fratta, G. L. Gessa: Stimulation Band 341, Nummer 1, April 2012, S. 274–284, ISSN 1521-0103. doi:10.1124/jpet.111.190132. PMID 22267202. H. Ashrafian, G. Czibik u. a.: Fumarate is cardioprotective Band 339, Nummer 2, November 2011, S. 530–536, ISSN 1521-0103. doi:10.1124/jpet.111.184119. PMID 21810934. PMC 3200001 (freier Volltext). 4-Methylmethcathinone Pharmacol Exp Ther. 315, Nr. 3, Dezember 2005, S. 1237–46. doi:10.1124/jpet.105.089805. PMID 16126840. Farkas S: Silperisone: a centrally acting muscle Band 328, Nummer 3, März 2009, S. 723–731, ISSN 1521-0103. doi:10.1124/jpet.108.149054. PMID 19106170. R. Hamanaka, T. Shinohara u.a.: Rescue of mutant Band 328, Nummer 3, März 2009, S. 723–731, ISSN 1521-0103. doi:10.1124/jpet.108.149054. PMID 19106170. R. Hamanaka, T. Shinohara u.a.: Rescue of mutant J. Pharmacol. Exp. Ther.. 325, Nr. 2, Mai 2008, S. 577–587. doi:10.1124/jpet.107.133348. PMID 18252809. M. C. Fidler, M. Sanchez u.a.: A One-Year Randomized 302, Nummer 3, September 2002, S. 1220–1227, ISSN 0022-3565. doi:10.1124/jpet.102.034280. PMID 12183683. freier Volltext R. H. Howland: Vilazodone: another Band 328, Nummer 3, März 2009, S. 723–731, ISSN 1521-0103. doi:10.1124/jpet.108.149054. PMID 19106170. R. Hamanaka, T. Shinohara u. a.: Rescue of mutant